No Data
No Data
Inhibikase Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Inhibikase Therapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : The Inhibikase Therapeutics (IKT.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $27.00 to $23.00.
HC Wainwright & Co. : The Inhibikase Therapeutics (IKT.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $27.00 to $23.00.
HC Wainwright & Co. Maintains Buy on Inhibikase Therapeutics, Lowers Price Target to $23
HC Wainwright & Co. analyst Edward White maintains Inhibikase Therapeutics (NASDAQ:IKT) with a Buy and lowers the price target from $27 to $23.
Inhibikase Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/21/2024 1170.72% HC Wainwright & Co. $27 → $23 Maintains Buy 03/07/2024 1391.71% HC Wainwright & Co. →
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Korro Bio (KRRO) and Inhibikase Therapeutics (IKT)
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ:IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to
No Data